Clinical Study

Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study

Table 1

Baseline characteristics.

CharacteristicWarfarin plus enoxaparin Rivaroxaban
()()

Male [% ()]49 (40)59 (45)
Age (years ± SD)63 ± 1555 ± 15
Classification [% ()]
 Stable74 (61)79 (60)
 Submassive23 (19)18 (14)
 Massive2 (2)3 (2)
CrCl admission (mL/minute ± SD)71 ± 2480 ± 28
Hgb admission (gm/dL ± SD)13 ± 2.013 ± 2.0
BMI (kg/m2  ± SD)32 ± 9.032 ± 8.4
HFrEF [% ()]4 (3)3 (2)
DM [% ()]23 (19)11 (8)
HTN [% ()]63 (52)49 (37)
CAD [% ()]15 (12)3 (2)
History DVT/PE [% ()]23 (19)20 (15)
INR discharge (±SD)1.9 ± 0.9N/A
INR ≥ 2 at discharge [% ()]44 (36)N/A

DM: diabetes mellitus, BMI: body mass index, CAD: coronary artery disease, CKD: chronic kidney disease, CrCl: creatinine clearance, CVA: cerebrovascular accident, DVT: deep vein thrombosis, HFrEF: heart failure with reduced ejection fraction, Hgb: hemoglobin, HTN: hypertension, and PE: pulmonary embolism.